Background. We investigated the incidence and outcome of progressive multifocal leukoencephalopathy (PML) in human immunodeficiency virus (HIV)-infected individuals before and after the introduction of combination antiretroviral therapy (cART) in 1996.
T cell count, whereas overall mortality was dependant on cART use and baseline CD4 + T cell count.
Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system (CNS) that is caused by lytic replication of JC virus in the CNS [1] [2] [3] . PML is rare but frequently fatal as observed in the context of profound cellular immu-introduction of combination antiretroviral therapy (cART) varied from 0.3% to 8%, with less than one-tenth surviving for 11 year [2, 10, 11] . Specific antiviral treatment targeting JC virus is lacking [12] [13] [14] [15] [16] , and improvement of JC virus-specific immunity after suppression of HIV replication is the mainstay of therapy. Data from early after the introduction of cART described less dramatic improvements for PML than for other opportunistic diseases [17] [18] [19] . More recent studies report a patient survival rate of up to 63%, but persisting neurologic deficits occur in more than one-half of the survivors [13, [20] [21] [22] [23] . Factors that appear to be associated with survival include PML as the primary manifestation of AIDS, high CD4 + T cell count, low HIV RNA load, presence of JC virus-specific cytotoxic T lymphocytes, and low JC viral load in cerebral spinal fluid (CSF) at diagnosis [23] [24] [25] [26] .
However, most data were obtained from retrospective case series or were limited by small numbers and inconsistent case definitions. The Swiss HIV Cohort Study (SHCS) provides the unique opportunity to investigate PML from prospectively collected data from over the past 20 years. The aim of this study was to assess the incidence rate and risk factors for mortality among HIV-infected individuals with PML.
PARTICIPANTS AND METHODS

Study participants.
The SHCS is a prospective, clinic-based, observational study of HIV-infected adults that was initiated in 1988, with clinical and laboratory follow-up documented every 6 months. Enrollment is independent of disease stage and treatment [27] . The present study included all patients who had received a diagnosis of PML from 1988 through August 2007. The diagnosis of PML has been encoded in the SHCS database as either definitive (i.e., proven by histologic examination of a biopsy or postmortem tissue specimen) or presumptive (i.e., according to clinical, radiological, or laboratory evidence). For the purpose of this study, diagnoses of PML in the SHCS database were checked by individual chart review, and confirmed diagnoses were classified using the following previously established definitions [28] : (1) possible, by typical neuroradiologic and clinical findings; (2) laboratory confirmed, when JC virus DNA was detected in CSF; (3) definitive, when confirmed by histologic examination of a brain biopsy or autopsy specimen. Data related to HIV infection, including age, sex, transmission risk, prior AIDS-defining conditions, CD4 + and CD8 + T cell counts, HIV RNA load, treatment history, and cause of death (using the International Statistical Classification of Diseases, 10th Revision [29] ) were obtained from the SHCS database. Additional data, such as clinical course, neuroradiological images, use of antiviral drugs, and supplementary laboratory values, were extracted from the chart review. After chart review, we excluded 10 patients who had received a diagnosis of another neurological disease and 30 additional patients who had received a diagnosis of presumed PML but lacked neuroradiological images; thus, data on 186 of 226 patients were used to estimate the annual PML prevalence. For the survival analysis, we excluded 25 additional patients for whom PML was only diagnosed postmortem and another 2 patients whose CD4 + T cell counts at diagnosis were missing. PML-attributable mortality was defined as death due to neurological deterioration, including seizures and coma, that was directly associated with PML. All-cause mortality was defined as death due to any cause, including PML-attributable death. To investigate the effect of cART on the incidence and outcome of PML, 2 successive eras were defined according to the introduction of cART in Switzerland in 1996: the pre-cART era (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) and the cART era (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) . cART was defined as at least 2 nucleoside reverse-transcriptase inhibitors plus either a protease inhibitor or a nonnucleoside reverse-transcriptase inhibitor. Monodrug and dual-drug ART were defined as 1 nucleoside reverse-transcriptase inhibitor or a combination of 2 nucleoside reverse-transcriptase inhibitors, respectively.
Statistics. Basic demographic characteristics, laboratory values, and use of ART were compared using the x 2 test for categorical variables and the Mann-Whitney U test for continuous variables. Incidence rates of PML were calculated using the number of enrolled patients in the SHCS and the duration of follow-up according to the 2 defined periods of 1988-1995 and 1996-2007 . Survival patterns were displayed using KaplanMeier plots of cumulative survival probabilities. Cox hazard proportional models were used to estimate the hazard ratios (HRs) of PML-attributable death during the first year after diagnosis of PML. All patients were censored at 1 year after diagnosis of PML if no death had occurred. Analyses were conducted using Stata software, version 9.2 (Stata), for Windows.
RESULTS
Patient characteristics. From 1988 through August 2007, 186
patients received a diagnosis of PML in the SHCS. Figure 1 shows that the annual PML prevalence was highest during the pre-cART era (mean prevalence during 1993-1995, 0.9%). From 1996 onward, the annual mean prevalence decreased to 0.1%. For the survival analysis, we included 159 of 186 patients. Table 1 summarizes the demographic characteristics of the 159 patients. The median age was 37 years (interquartile range [IQR]: 33-42 years); 74.2% of the patients were male. Of the 159 analyzed patients, only 3 (1.9%) were of non-white ethnicity. Almost one-half of the patients had prior AIDS-defining conditions. It was not unexpected that Candida esophagitis and Pneumocystits pneumonia were the most frequently diagnosed diseases in patients with PML who had prior AIDS-defining disease. Only 5 patients had received a diagnosis of cytomegalovirus retinitis, and 6 had received a diagnosis of Kaposi sarcoma, which could not be further analyzed. The median CD4 + T cell count at PML diagnosis was 60 cells/mL (IQR, 23-140 cells/mL). Plasma HIV RNA levels were available for 68 patients; the median was 4.9 log 10 copies/mL (IQR, 3.5-5.4 log 10 copies/mL). Most patients (71.7%) were receiving ART when PML was diagnosed, but only 30.8% were receiving cART. Injection drug use was an HIV transmission risk factor for onehalf of the patients, and one-third of the patients were men who have sex with men. PML was diagnosed on the basis of typical clinical and neuroradiological signs in 95 patients (60%), was laboratory confirmed in 38 patients (24%), and was definitive in 26 patients (16%). Magnetic resonance imaging was performed for 133 patients (84%). Polymerase chain reaction (PCR) of CSF specimens for JC virus DNA was performed for 81 patients (51%), and JC virus DNA was detectable in approximately one-half of these patients. The 25 patients with a postmortem diagnosis were similar with regard to baseline age, sex, transmission risk, and CD4 + T cell count at baseline; however, these patients had more frequently received a diagnosis of another AIDS-defining condition before 1996 than from 1996 onward.
Outcome of PML in Switzerland. After diagnosis of PML, 25 (15.7%) patients started cART, 8 (5.0%) received cidofovir, and 2 (1.2%) received cytarabine. Overall, 97 patients died within 1 year after diagnosis; the median survival time was 90 days (IQR, 53-312 days), which corresponds to a 1-year mortality rate of 119.0 deaths per 100 person-years (PY; 95% CI, 98.1-144.4 deaths per 100 PY). Of those 97 patients, 51 died of PML, corresponding to a PML-attributable 1-year mortality rate of 58.9 deaths per 100 PY (95% CI, 44.8-77.6 deaths per 100 PY). The median time from diagnosis to PML-attributable death was 71 days (IQR, 44-140 days). Of 62 patients with PML who lived for 11 year after diagnosis, long-term followup data were available for 47. Of these 47 patients, 39 (83%) had persisting neurological deficits and only 8 (17%) showed clinical improvement.
PML during the pre-cART and cART eras. Of 159 patients with PML, 89 (56.0%) received a diagnosis during the period 1988-1995 and 70 (44.0%) received a diagnosis during the period 1996-2007. The incidence rate of PML decreased by 4-fold from 0.24 cases per 100 PY (95% CI, 0.20-0.29 cases per 100 PY) during the pre-cART era to 0.06 cases per 100 PY (95% CI, 0.04-0.10 cases per 100 PY) during the cART era. Sex, transmission risk, and importantly, CD4 + T cell counts were similar in the 2 groups (table 1) . Individuals in the precART era had significantly more prior AIDS-defining conditions ( ), were more likely to have been receiving P p .007 monodrug or dual-drug ART ( ), and more frequently P ! .001 received a diagnosis of possible PML ( ), compared P p .002 with patients in the cART era.
Risk factors for PML-attributable mortality. The PMLattributable 1-year mortality rate decreased by approximately one-half, from 82.3 deaths per 100 PY (95% CI, 58.8-115.1 deaths per 100 PY) during the pre-cART era to 37.6 deaths per In the univariate analysis, patients treated with cART (HR, 0.20; 95% CI, 0.09-0.48;
) and those who received a P ! .001 diagnosis from 1996 onward (HR, 0.50; 95% CI, 0.28-0.90; ) had a lower risk of PML-attributable death within P p .020 the first year after PML diagnosis (table 2), compared with patients who were not treated with cART and received a diagnosis before 1996. We did not observe any association between female sex and survival (HR, 1.51; 95% CI, 0.85-2.69; ) when all patients were included (table 2) or when P p .159 only injection drug users were considered (HR, 1.06; 95% CI, 0.50-2.27;
). In the multivariate analysis, after adjust-P p .881 ment for age, CD4 + T cell count, ART, and calendar period, treatment with cART at PML diagnosis was the only prognostic factor for survival (HR, 0.18; 95% CI, 0.07-0.50; ) (table P ! .001 3). cART use also remained the only prognostic factor when HIV RNA load was included in a model (HR, 0.25; 95% CI, 0.08-0.79; ) with 68 patients whose HIV RNA load data P p .01 were available. Kaplan-Meier estimates, stratified by treatment modality at PML diagnosis, are shown in figure 3 .
Risk factors for all-cause mortality. In the univariate analysis, a CD4 + T cell count 1100 cells/mL (HR, 0.66; 95% CI, 
DISCUSSION
PML is a devastating disease that confronts patients and physicians with progressive disability and high mortality. Although the pathology and its viral etiology have been known for 140 years [30, 31] , PML has been difficult to study, in part, because of the erratic manifestation in patients characterized by severe chronic conditions with profound cellular immunodeficiency. This hallmark has also been emphasized in the recent PML cases in patients with autoimmune diseases treated with new potent immunosuppressive therapies [4] [5] [6] [7] [8] [9] . Even for patients with HIV infection or AIDS, in whom most cases occurred in the past, few studies enrolled 150 patients with consistently collected longitudinal data [13, 22, 23, 26] .
Our comprehensive study of almost 200 PML cases diagnosed over 20 years of the SHCS enumerates the incidence rate of PML as 0.24% during the pre-cART era of HIV infection and AIDS. The introduction of cART in Switzerland in 1996 was associated with a 4-fold decrease in PML incidence to 0.06%. The decrease in PML incidence from 1996 onward supports the notion that preservation of overall immune functions by cART is a key factor protecting against the manifestation of PML. Indeed, we found that the median CD4 + T cell counts were similarly low in both eras (60 cells/mL and 70 cells/mL during the pre-cART and cART eras, respectively) at the time of PML diagnosis. In addition to preventing decreases in CD4 + T cell count, however, cART-mediated suppression of HIV replication may exert a direct beneficial effect in the CNS by interfering with HIV-tat mediated activation of JC virus replication [32, 33] .
Our study also revealed that cART has significantly reduced the PML-attributable 1-year mortality rate from 82.3 deaths per 100 PY during the pre-cART era to 37.6 deaths per 100 PY during the cART era. This improvement of the 1-year survival rate in association with cART was independent of HIV RNA load and the total CD4 + T cell count at diagnosis. However, a case-control study that compared HIV-infected patients with PML and HIV-infected control subjects matched by CD4 + T cell count supports the view that the JC virus-specific T cell responses, not the overall CD4
+ T cell count, may be critical for PML survival [34] ; JC virus-specific cytotoxic CD8 + T cell responses seem to be the most critical [24] . Conversely, our study indicated that all-cause mortality among patients with PML was associated with a lower CD4 + T cell count at baseline, which reflects the higher risk of opportunistic disease burden with increasing immunodeficiency. No corresponding data from other immunodeficient HIV-uninfected patients are available, but case series support the view that the prognosis of PML may be significantly worse in conditions that do not allow improvement of anti-JC virus immunity without adverse outcomes for the underlying condition (e.g., neoplasia, transplantation, or autoimmune disease) [6, 35, 36] . On the other hand, brisk recovery of immunity may cause immune reconstitution inflammatory syndrome (IRIS), a potentially fatal complication after initiation of cART [37] [38] [39] . The frequency of IRIS may be more pronounced among patients with low CD4 + cell counts [38] . The rate of IRIS among patients with PML varied considerably between different studies and was as high as 23% [40] . In our study, only 4 patients (2.5%) with IRIS were reported in the SHCS, most likely because of underdiagnosis. Of interest, in a recent study, no difference in mortality among patients with PML with or without IRIS was observed [40] .
PML is typically diagnosed on the basis of examination of focal neurological deficits in immunodeficient patients and represents a late complication of HIV infection or AIDS. Therefore, during the cART era, patients with PML must have either received a late diagnosis of HIV infection or must have had deferred treatment because of personal choice, drug intolerance, or comorbidities, including psychiatric disorders. In this context, it is interesting to note that there was a higher proportion of injection drug users among patients with PML in both eras, compared with the entire SHCS population. However, we cannot exclude that injection drug use might also represent a behavioral risk factor for JC virus transmission.
Limitations of our study are those inherent to observational cohort studies in which patients are not randomized. Therefore, diagnosis, examination, and interventions are dependent on the treating physician and are subject to selection bias. The gold standard of PML diagnosis is histologic examination of a brain biopsy specimen, which is highly specific but also invasive and costly, and results may be false negative as a result of necrosis [41] . Detection of JC virus in CSF by PCR became available in the 1990s and is now widely accepted for laboratory-confirmed diagnosis [28] . In HIV-infected patients with typical radiological lesions, the specificity of JC virus PCR of CSF is 190%, but the sensitivity ranges from 70% to 90% [42, 43] . In the SHCS, JC virus DNA was not detectable in CSF specimens from two-thirds of patients who received a histological diagnosis. In addition, we cannot account for changes in these parameters, because the methodology of JC virus detection in CSF changed from nested PCR to a real-time format during the past 10 years. Therefore, neither the performance of the JC virus PCR test used at the SHCS centers nor the potential role of the test result as a marker for patient survival could be assessed. A recent study reported that the sensitivity of JC virus DNA detection decreased from 90% to ∼60% during the cART era. Exposure to cART and a high CD4 + T cell count were identified as predictors of diagnostic failure [44] . Therefore, PML diagnosis is frequently based on compatible clinical and radiological findings. Together, these emphasize the need for cautious interpretation of negative CSF findings in patients with otherwise typical PML.
To date, there are no successful antiviral therapies for PML that effectively suppress JC virus replication. In HIV-infected patients with PML, the additional use of cidofovir, a nucleotide analogue with in vitro activity against JC virus, has shown contradictory results in several studies [12] [13] [14] [15] [16] . A prospective nonrandomized analysis and a recent large multicenter cohort study report lack of additional efficacy with the addition of cidofovir to cART [13, 16] . In our population, cytarabine and cidofovir were rarely used, and the efficacy of these drugs could not be investigated.
In conclusion, the results of this study, covering 20 years of the SHCS database, demonstrate that the introduction of cART has led to a decrease in the incidence of PML among HIVinfected patients and has reduced PML-attributable 1-year mortality, regardless of baseline CD4 + T cell count.
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